NCT06119685 2025-06-03IDP-023 as a Single Agent and in Combination With Antibody Therapies in Patients With Advanced Hematologic CancersIndapta Therapeutics, INC.Phase 1/2 Recruiting128 enrolled
NCT01084252 2024-11-01Phase 1/2 Dose Escalation and Efficacy Study of Anti-CD38 Monoclonal Antibody in Patients With Selected CD38+ Hematological MalignanciesSanofiPhase 1/2 Completed351 enrolled 56 charts